Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum

The latest update is out from Galmed Pharmaceuticals ( (GLMD) ).

On August 14, 2025, Galmed Pharmaceuticals Ltd. attempted to hold a Special General Meeting of Shareholders, but it was adjourned due to a lack of quorum. The meeting is rescheduled for August 15, 2025, at the same location. This delay could impact the company’s decision-making processes and timelines, potentially affecting its strategic initiatives and stakeholder interests.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. operates within the pharmaceutical industry, focusing on the development of innovative drugs for the treatment of liver diseases and other related conditions.

Average Trading Volume: 317,148

Technical Sentiment Signal: Sell

Current Market Cap: $3.21M

Learn more about GLMD stock on TipRanks’ Stock Analysis page.